In recent years, there has been a dramatic increase in the popularity and use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes and obesity [1]. This evidence concerns the gene GCG and type 2 diabetes mellitus.